# DEPARTMENT OF SOCIAL AND HEALTH SERVICES HEALTH AND RECOVERY SERVICES ADMINISTRATION Olympia, Washington

To: Pharmacists Memorandum No: 06-32
All Prescribers Issued: May 31, 2006

Nursing Home Administrators

Managed Care Organizations For information, contact Provider

**Relations at:** 800.562.3022 or

http://maa.dshs.wa.gov/contact/prucontact.asp

**From:** Douglas Porter, Assistant Secretary

Health and Recovery Services or visit the pharmacy web site at:
Administration (HRSA) http://maa.dshs.wa.gov/pharmacy

Subject: Prescription Drug Program: Washington Preferred Drug List and Expedited

**Prior Authorization Changes** 

Effective for claims with dates of service on and after July 1, 2006, unless otherwise noted, HRSA will implement the following changes to the Prescription Drug Program:

Additions to the Washington Preferred Drug List (PDL);

- Changes to the Washington PDL retroactive to dates of service on and after April 1, 2006;
- Additions to Expedited Prior Authorization (EPA) codes and criteria;
- The removal of an EPA code; and
- A change in the criteria for an EPA code.

### Therapeutic Drug Class Additions to the Washington Preferred Drug List (PDL)

Therapeutic Drug Class	Preferred Drugs	Non-preferred Drugs
Antiemetics	Generic:	Generic:
	<b>Brand:</b> Zofran®/ODT® ( <i>ondansetron</i> )* tablet/solution/injection/IV	Brand: Aloxi® (palonosetron) Injection* Anzemet® (dolasetron) tablet/injection* Kytril® (granisetron) tablet/solution/ injection*
	*EPA required	*EPA required

Therapeutic	Preferred Drugs	Non-preferred Drugs	
<b>Drug Class</b>			
Targeted Immune	Generic:	Generic:	
Modulators			
	Brand:	Brand:	
	Enbrel <sup>®</sup> (etanercept)*	Humira® (adalimumab)*	
	Remicade® (infliximab)*	Kineret® (anakinra)*	
		Raptiva <sup>®</sup> (efalizumab)*	
	*EPA required	*EPA required	

## Changes to the Washington PDL Retroactive to Dates of Service on and After April 1, 2006

Therapeutic Drug Class	Preferred Drugs	Non-preferred Drugs
Attention Deficit/Hyperact ivity Disorder  (*Not subject to TIP. See pg. M.1.)	Generic: amphetamine salt combo dextroamphetamine dextroamphetamine SA methylphenidate methylphenidate SA Methylin® (methylphenidate)  Brand: Adderall XR® (amphet asp/amphet/d-amphet) Concerta® (methylphenidate) Focalin® (dexmethylphenidate) Focalin XR® (dexmethylphenidate) Metadate CD® (methylphenidate) Ritalin LA® (methylphenidate) Strattera® (atomoxetine hcl)	Generic: pemoline  Brand: Adderall® (amphet asp/amphet/d-amphet) Dexedrine® (d-amphetamine) Dexedrine SA® (d-amphetamine) Dextrostat® (d-amphetamine) Metadate ER® (methylphenidate) Methylin® (methylphenidate) chewable/solution Methylin ER® (methylphenidate) Ritalin® (methylphenidate) Ritalin® (methylphenidate) Ritalin SR® (methylphenidate)

#### **Expedited Prior Authorization (EPA) Changes**

Effective the week of July 1, 2006:

#### **EPA Code Removed:**

Drug	Code	Criteria
Remicade Injection®	022	Treatment of rheumatoid arthritis in combination
(infliximab)		with methotrexate when prescribed by a rheumatologist in those patients who have had an inadequate response to methotrexate alone.

#### **New EPA Codes and Criteria:**

Drug	Code	Criteria
Aloxi <sup>®</sup> Injection	129	Administered as a single dose in conjunction with
(palonosetron)		cancer chemotherapy treatment.
<b>Amitiza</b> <sup>®</sup> (lubiprostone)	007	Treatment of chronic constipation. Must have tried
		and failed a less costly alternative.
<b>Humira</b> ® (adalimumab)	026	Treatment of psoriatic arthritis when prescribed by a
		rheumatologist or dermatologist for patients who
		have tried and failed one or more DMARD. Dose
		not to exceed 40mg subcutaneously every 2 weeks if
		patient is also receiving methotrexate, or up to 40mg
		subcutaneously every week if patient is not receiving
		methotrexate concomitantly.
<b>Raptiva</b> <sup>®</sup> (efalizumab)	027	Treatment of plaque psoriasis when prescribed by a
		dermatologist for patients 18 years or older. Weekly
		dose is not to exceed 200mg subcutaneously.

#### **Change in Criteria for EPA Code:**

Drug	Code	Criteria
Remicade Injection®	023	Treatment of Crohn's disease or ulcerative colitis
(infliximab)		when prescribed by a gastroenterologist in those
		patients who have tried and failed conventional
		therapy. Maximum dose is 10mg/kg given every 4
		weeks.

#### **Billing Instructions Replacement Pages**

Attached are replacement pages H.7-H.8, H.11-H.12, H.15-H.16, and N.1-N.12 for HRSA's *Prescription Drug Program Billing Instructions*.

#### How do I conduct business electronically with HRSA?

You may conduct business electronically with HRSA by accessing WaMedWeb at <a href="https://wamedweb.acs-inc.com">https://wamedweb.acs-inc.com</a>.

#### How can I get HRSA's provider issuances?

To obtain HRSA's provider numbered memoranda and billing instructions, go to HRSA's website at <a href="http://maa.dshs.wa.gov">http://maa.dshs.wa.gov</a> (click on the *Billing Instructions/Numbered Memoranda* or *Provider Publications/Fee Schedules link*).

To request a free paper copy from the Department of Printing:

- 1. **Go to: www.prt.wa.gov** (Orders filled daily.)
  - a) Click *General Store*.
  - b) If a **Security Alert** screen is displayed, click **OK**.
    - i. Select either *I'm New* or *Been Here*.
    - ii. If new, fill out the registration and click *Register*.
    - iii. If returning, type your email and password and then click *Login*.
  - c) At the **Store Lobby** screen, click **Shop by Agency**. Select **Department of Social** and **Health Services** and then select **Health and Recovery Services Administration**.
  - d) Select *Billing Instructions*, *Forms*, *Healthy Options*, *Numbered Memo*, *Publications*, or *Document Correction*. You will then need to select a year and then select the item by number and title.
- 2. **Fax/Call:** Dept. of Printing/Attn: Fulfillment at FAX (360) 586-6361/ telephone (360) 586-6360. (Orders may take up to 2 weeks to fill.)

Drug	Code	Criteria
<b>Abilify</b> <sup>®</sup> (aripiprazole)	015	All of the following must apply:
( 4.4)		<ul><li>a) There must be an appropriate DSM IV diagnosis; and</li><li>b) Patient is 6 years of age or older.</li></ul>
Accutane® (isotretinoin)		Must not be used by patients who are pregnant or who may become pregnant while undergoing treatment. The following conditions must be <b>absent</b> :
		<ul><li>a) Paraben sensitivity;</li><li>b) Concomitant etretinate therapy; and</li><li>c) Hepatitis or liver disease.</li></ul>
	001	Diagnosis of severe (disfiguring), recalcitrant cystic acne, unresponsive to conventional therapy.
	002	Diagnosis of severe, recalcitrant acne rosacea in adults unresponsive to conventional therapy.
	003	Diagnosis of severe keratinization disorders when prescribed by, or in consultation with, a dermatologist.
	004	Prevention of skin cancers in patients with xeroderma pigmentosum.
	005	Diagnosis of mycosis fungoides (T-cell lymphoma) unresponsive to other therapies.
Adderall® (amphetamine/ dextro-	<del>026</del>	Diagnosis of Attention Deficit /Hyperactivity Disorder (ADHD) or Attention Deficit Disorder (ADD) and the prescriber is an authorized schedule II prescriber.
amphetamine)	027	Diagnosis of narcolepsy by a neurologist or sleep specialist, following documented positive sleep latency testing and the prescriber is an authorized schedule II prescriber.
	<del>087</del>	Depression associated with end-stage illness and the prescriber is an authorized schedule II prescriber.

Drug	Code	Criteria
Aggrenox <sup>®</sup> (aspirin/dipyridam ole)	037	To reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis, and all of the following:
		a) The patient has tried and failed aspirin or dipyridamole alone; and
		b) The patient has no sensitivity to aspirin.
Aloxi® Injection (palonosetron)	129	Administered as a single dose in conjunction with cancer chemotherapy treatment
<b>Altace</b> <sup>®</sup> (ramipril)	020	Patients with a history of cardiovascular disease.
Ambien® (zolpidem tartrate)	006	Treatment of insomnia. Drug therapy is limited to 10 units in 30 days.
Ambien CR® (zolpidem tartrate)		See criteria for Ambien <sup>®</sup> .
Amitiza® (lubiprostone)	007	Treatment of chronic constipation. Must have tried and failed a less costly alternative.
Angiotensin Receptor Blockers (ARBs)	092	Must have tried and failed, or have a clinically documented intolerance to an angiotensin converting enzyme (ACE) inhibitor.
Atacand H Avalide® (i Avapro® (i Benicar® (i Cozaar® (la Diovan HC Hyzaar® (l Micardis® Micardis H Teveten® (i	CT® (control of the control of the c	an) tan medoxomil) potassium) sartan/HCTZ) potassium/HCTZ)

Drug	Code	Criteria
Fazaclo <sup>®</sup>	012	All of the following must apply:
(clozapine)		<ul> <li>a) There must be an appropriate DSM IV diagnosis present as determined by a qualified mental health professional; and</li> <li>b) Patient is 18 years of age or older; and</li> <li>c) Must be prescribed by a psychiatrist, neurologist, or psychiatric ARNP with prescriptive authority approved for</li> </ul>
		this drug class, or in consultation with one of the above; and d) Must have tried and failed generic clozapine.
Focalin®		See criteria for Concerta®
(dexmethylphenidat e HCl)		
Focalin XR® (dexmethylphenidat	<del>061</del>	Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and all of the following
<del>e HCl)</del>		a) The prescriber is an authorized schedule II prescriber;
		b) Total daily dose is administered as a single dose; and
		e) The patient is six years of age or older.
Gabitril <sup>®</sup> (tiagabine HCl)	036	Treatment of seizures.
Geodon®	046	All of the following must apply:
(ziprasidone HCl)		<ul><li>a) There must be an appropriate DSM IV diagnosis; and</li><li>b) Patient is 6 years of age or older.</li></ul>
Zyp prol myo	rexa <sup>®</sup> ), ongation ocardial	codon® prolongs the QT interval (< Seroquel® > Risperdal® > it is contraindicated in patients with a known history of QT in (including a congenital long QT syndrome), with recent acute infarction, or with uncompensated heart failure; and in combination lrugs that prolong the QT interval.
Geodon® IM	058	All of the following must apply:
Injection		a) Diagnosis of acute agitation associated with schizophrenia;
(ziprasidone		b) Patient is 18 years of age or older; and
mesylate)		c) Maximum dose of 40mg per day and no more than 3 consecutive days of treatment.
Glycolax Powder <sup>®</sup> (polyethylene glycol)	021	Treatment of occasional constipation. Must have tried and failed a less costly alternative.

(Rev: 03/01/06, Eff: 04/01/06) - H.11 - **Expedited Prior Authorization (EPA) # Memo 06-12 Denotes change** 

Drug	Code	Criteria
Humira® (adalimumab)	026	Treatment of psoriatic arthritis when prescribed by a rheumatologist or dermatologist for patients who have tried and failed one or more DMARD. Dose not to exceed 40mg subcutaneously every 2 weeks if patient is also receiving methotrexate, or up to 40mg subcutaneously every week if patient is not receiving methotrexate concomitantly.
Humira Injection <sup>®</sup> (adalimumab)	028	Treatment of rheumatoid arthritis when prescribed by a rheumatologist for patients who have tried and failed one or more DMARD. Dose not to exceed 40mg subcutaneously every 2 weeks if patient is also receiving methotrexate, or up to 40mg subcutaneously every week if patient is not receiving methotrexate concomitantly.
Infergen® (interferon alphcon-1)	134	Treatment of chronic hepatitis C in patients 18 years of age and older with compensated liver disease who have anti-HCV serum antibodies and/or presence of HCV RNA.
Intron A <sup>®</sup> (interferon	030	Diagnosis of hairy cell leukemia in patients 18 years of age and older.
alpha-2b recombinant)	031	Diagnosis of recurring or refractory condyloma acuminate (external genital/perianal area) for intralesional treatment in patients 18 years of age and older.
	032	Diagnosis of AIDS-related Kaposi's sarcoma in patients 18 years of age and older.
	033	Diagnosis of chronic hepatitis B in patients 1 year of age and older.
	107	Diagnosis of malignant melanoma in patients 18 years of age and older.
	109	Treatment of chronic hepatitis C in patients 18 years of age and older.
	135	Diagnosis of follicular non-Hodgkin's lymphoma in patients 18 years of age and older.
Kadian <sup>®</sup> (morphine sulfate)	040	Diagnosis of cancer-related pain.
<b>Keppra</b> <sup>TM</sup> (levetiracetam)		See criteria for Gabitril®
Kineret Injection <sup>®</sup> (anakinra)	029	Treatment of rheumatoid arthritis when prescribed by a rheumatologist for patients 18 years of age and older who have tried and failed one or more DMARD. Daily dose not to exceed 100mg subcutaneously.

(Rev: 05/31/2006 Eff: 07/01/2006) - H.12 - **Expedited Prior Authorization (EPA) # Memo 06-32** Denotes change

Drug	Code	Criteria
Oxandrin® (oxandrolone)		Before any code is allowed, there must be an absence of all of the following:
		<ul> <li>a) Hypercalcemia;</li> <li>b) Nephrosis;</li> <li>c) Carcinoma of the breast;</li> <li>d) Carcinoma of the prostate; and</li> <li>e) Pregnancy.</li> </ul>
	110	Treatment of unintentional weight loss in patients who have had extensive surgery, severe trauma, chronic infections (such as AIDS wasting), or who fail to maintain or gain weight for no conclusive pathophysiological cause.
	111	To compensate for the protein catabolism due to long-term corticosteroid use.
	112	Treatment of bone pain due to osteoporosis.
OxyContin® (oxycodone HCI)	040	Diagnosis of cancer-related pain.
Parcopa® (carbidopa/levodop a)	049	Diagnosis of Parkinson's disease and one of the following:  a) Must have tried and failed generic carbidopa/levodopa; or b) Be unable to swallow solid oral dosage forms.
PEG-Intron <sup>®</sup> (peginterferon alpha 2b)	109	Treatment of chronic hepatitis C in patients 18 years of age or older.
Pegasys <sup>®</sup> (peginterferon alpha-2a)	109	Treatment of chronic hepatitis C in patients 18 years of age or older.
Plavix® (clopidogrel bisulfate)	116	When used in conjunction with stent placement in coronary arteries. Supply limited to 9 months after stent placement.
-	136	For use in patients with atherosclerosis documented by recent myocardial infarction, recent stroke, or established peripheral artery disease and have failed aspirin. A patient that is considered an aspirin failure has had an atherosclerotic event (MI, stroke, intermittent claudication) after the initiation of once-a-day aspirin therapy.

(Rev: 11/15/05, Eff: 12/1/05) - H.15 - **Expedited Prior Authorization (EPA)** 

Drug	Code	Criteria
Pravachol® (pravastatin sodium)	039	Patient has a clinical drug-drug interaction with other statin-type cholesterol-lowering agents.
Prevacid <sup>®</sup> Solutab (lansoprazole)	050	Inability to swallow oral tablets or capsules.
Pulmozyme <sup>®</sup> (dornase alpha)	053	Diagnosis of cystic fibrosis and the patient is 5 years of age or older.
Raptiva® (efalizumab)	027	Treatment of plaque psoriasis when prescribed by a dermatologist for patients 18 years or older. Weekly dose is not to exceed 200mg subcutaneously.
<b>Rebetol</b> ® (ribavirin)		See criteria for Copegus <sup>®</sup> .
Rebetron® (ribaviron /interferon alpha-2b, recombinan	008	Treatment of chronic hepatitis C in patients with compensated liver disease who have relapsed following alpha interferon therapy.
	009	Treatment of chronic hepatitis C in patients with compensated liver disease.
Remicade Injection (infliximab)	n <sup>®</sup> 023	Treatment of Crohn's disease or ulcerative colitis when prescribed by a gastroenterologist in those patients who have tried and failed conventional therapy. Maximum dose is 10mg/kg given every 4 weeks.
Rena-Vite <sup>®</sup> Rena-Vite RX <sup>®</sup> (folic acid/vit B comp W-C)	096	Treatment of patients with renal disease.
ReVia <sup>®</sup> (naltrexone HCl)	067	Diagnosis of past opioid dependency or current alcohol dependency.
		Must be used as adjunctive treatment within a state-certified intensive outpatient chemical dependency treatment program. See WAC 388-805-610. For maintenance of opioid-free state in a detoxified person, treatment may be started only after a minimum of 7-10 days free from opioid use. Treatment period must be limited to 12 weeks or less, and the patient must have an absence of all of the following:

(Rev: 05/31/2006 Eff: 07/01/2006) - H.16 - **Expedited Prior Authorization (EPA) # Memo 06-32 Denotes Change** 

## Washington Preferred Drug List

#### What is the Washington Preferred Drug List?

HRSA, in coordination with the Health Care Authority (HCA) and Labor & Industries (L & I), have developed a list of preferred drugs within a selected therapeutic class that are selected based on clinical evidence of safety, efficacy, and effectiveness.

HRSA requires pharmacies to obtain prior authorization for nonpreferred drugs when a therapeutic equivalent is on the preferred drug list(s) (PDL).

**Note:** HRSA changed the format for multiple drug listings. A slash ( / ) is used to denote multiple forms of a drug. For example: "Cardizem® /CD/LA/SR" represents immediate release Cardizem, as well as the CD, LA, and SR forms. A hyphen ( - ) is used to indicate combination products. For example: "Benazepril-HCTZ" represents the combination product of Benazepril and Hydrochlorothiazide, rather than Benazepril AND the combination product.

Drug Class	Preferred Drugs	Non-preferred Drugs
ACE Inhibitors	Generic:	Brand:
	Captopril	Accupril® (quinapril)
	Enalapril	Aceon <sup>®</sup> (perindopril)
	Lisinopril	Capoten® (captopril)
	Benazepril	Mavik <sup>®</sup> (trandolapril)
	_	Monopril® (fosinopril)
	Brand:	Prinivil <sup>®</sup> ( <i>lisinopril</i> )
	Altace® (ramipril)*	Univasc <sup>®</sup> ( <i>moexipril</i> )
		Vasotec® (enalapril)
	*EPA required	Zestril <sup>®</sup> (lisinopril)
Antiemetics	Generic:	Generic:
	Brand:	Brand:
	Zofran <sup>®</sup> /ODT <sup>®</sup>	Aloxi <sup>®</sup> (palonosetron)
	(ondansetron)*	Injection*
	tablet/solution/injection/IV	Anzemet <sup>®</sup> (dolasetron)
		tablet/injection*
		Kytril <sup>®</sup> (granisetron)
		tablet/solution/
		injection*
	*EPA required	*EPA required

Drug Class	Preferred Drugs	Non-preferred Drugs
Antiplatelets	Brand:	Generic:
	Aggrenox®	ticlopidine
(*Not subject to TIP. See pg.	(aspirin/dipyridamole)*	1
M.1.)	Plavix <sup>®</sup> (clopidogrel	Brand:
,	bisulfate)*	Ticlid <sup>®</sup> (ticlopidine)
	*EPA required	
Attention Deficit/Hyperactivity	Generic:	Generic:
Disorder	amphetamine salt combo	pemoline
	dextroamphetamine	
(*Not subject to TIP. See pg.	dextroamphetamine SA	Brand:
M.1.)	methylphenidate	Adderall® (amphet
	methylphenidate SA	asp/amphet/d-amphet)
	Methylin <sup>®</sup>	Dexedrine® (d-amphetamine)
	(methylphenidate)	Dexedrine SA® (d-
		amphetamine)
	Brand:	Dextrostat® (d-amphetamine)
	Adderall XR <sup>®</sup> (amphet	Metadate ER®
	asp/amphet/d-amphet)	(methylphenidate)
	Concerta®	Methylin <sup>®</sup> (methylphenidate)
	(methylphenidate)	chewable/solution
	Focalin®	Methylin ER <sup>®</sup>
	(dexmethylphenidate)	(methylphenidate)
	Focalin XR®	Ritalin® (methylphenidate)
	(dexmethylphenidate)	Ritalin SR®
	Metadate CD®	(methylphenidate)
	(methylphenidate)	
	Ritalin LA®	
	(methylphenidate)	
	Strattera® (atomoxetine	
	hcl)	

#### **Prescription Drug Program**

Drug Class	Preferred Drugs	Non-preferred Drugs
Beta Blockers	Generic:	Generic:
	Atenolol	Acebutolol
	Metoprolol	Betaxolol
	Nadolol	Bisoprolol
	Pindolol	Labetalol
	Propranolol /ER	-
	Timolol	Brand:
		Blocadren® (timolol)
	Brand:	Cartrol <sup>®</sup> (carteolol)
	Coreg <sup>®</sup> (carvedilol)*	Corgard <sup>®</sup> (nadolol)
		Inderal® /LA
		(propranolol)
		Innopran XL <sup>®</sup> (propranolol)
		Kerlone <sup>®</sup> (betaxolol)
		Levatol® (penbutolol)
		Lopressor® (metoprolol)
		Normodyne <sup>®</sup> (labetalol)
		Sectral <sup>®</sup> (acebutolol)
		Tenormin <sup>®</sup> (atenolol)
		Toprol XL <sup>®</sup> (metoprolol
		succinate)
		Trandate <sup>®</sup> (labetalol)
		Visken <sup>®</sup> (pindolol)
	*EPA required	Zebeta <sup>®</sup> (bisoprolol)

Drug Class	Preferred Drugs	Non-preferred Drugs
Calcium Channel Blockers	Generic:	Generic:
	Diltiazem /XR	felodipine
	Nifedipine XR	nicardipine
	Verapamil /XR	
		Brand:
	Brand:	Adalat <sup>®</sup> /CC (nifedipine)
	Norvasc® (amlodipine)	Calan® /SR (verapamil)
		Cardene® /SR (nicardipine)
		Cardizem <sup>®</sup> /CD/LA/SR
		(diltiazem)
		Cartia XT <sup>®</sup> (diltiazem)
		Dilacor® XR (diltiazem)
		Diltia XT <sup>®</sup> ( <i>diltiazem</i> )
		DynaCirc® /CR (isradipine)
		Isoptin <sup>®</sup> /SR (verapamil)
		Plendil <sup>®</sup> ( <i>felodipine</i> )
		Procardia <sup>®</sup> /XL (nifedipine)
		Sular <sup>®</sup> (nisoldipine)
		Taztia XT <sup>®</sup> (diltiazem)
		Tiazac <sup>®</sup> (diltiazem)
		Vascor <sup>®</sup> (bepridil)
		Verelan®/PM (verapamil)
Drugs to treat Alzheimer's Disease	Brand:	Cognex <sup>®</sup> (tacrine)
	Aricept <sup>®</sup> (donepezil)	
	Exelon <sup>®</sup> (rivastigmine)	
	Razadyne <sup>®</sup> (galantamine)	
	Namenda <sup>®</sup> (memantine)	

Drug Class	Preferred Drugs	Non-preferred Drugs
Estrogens	Generic:	Generic:
	estradiol tablets	
		Brand:
	Brand:	Cenestin <sup>®</sup> (synthetic
	Menest® (esterified	conjugated estrogens)
	estrogens)	Climara <sup>®</sup> (estradiol)
	Premarin <sup>®</sup> cream	transdermal
	(conjugated equine	Esclim <sup>®</sup> (estradiol)
	estrogen vaginal cream)	transdermal
		Estrace <sup>®</sup> (estradiol)
		oral/vaginal
		Estraderm <sup>®</sup> transdermal
		Estring <sup>®</sup> (estradiol) vaginal
		ring
		Femring <sup>®</sup> (estradiol) vaginal
		ring
		Ogen <sup>®</sup> (estropipate)
		Premarin <sup>®</sup> (conjugated
		estrogens) oral
		Vagifem® (estradiol) vaginal
		tablets
		Vivelle®/DOT (estradiol)
		transdermal
Histamine-2 Receptor Antagonist	Generic:	Generic:
(H2RA) (*Not subject to TIP. See	ranitidine	cimetidine
pg. M.1.)		famotidine
		nizatidine
		David.
		Brand:
		Axid <sup>®</sup> (nizatidine)
		Tagainet (cimendine)
		Pepcid <sup>®</sup> (famotidine) Tagamet <sup>®</sup> (cimetidine) Zantac <sup>®</sup> (ranitidine)

Drug Class	Preferred Drugs	Non-preferred Drugs
Inhaled Corticosteroids	Generic:	Generic:
	Brand: Aerobid/Aerobid-M® (flunisolide MDI) Azmacort® (triamcinolone acetonide MDI) Flovent® (fluticasone propionate MDI) Flovent Rotadisk® (fluticasone propionate DPI) Qvar® (beclomethasone dipropionate MDI) Pulmicort Respules® (budesonide inhalation suspension)	Brand: Pulmicort Turbuhaler® (budesonide DPI)
Insulin-release stimulant type oral hypoglycemics	Generic immediate release: glyburide glipizide glyburide micronized	Generic: chlorpropamide tolazamide tolbutamide glipizide XR
		Brand: Amaryl® (glimepiride) Diabinese® (chlorpropamide) DiaBeta® (glyburide) Glucotrol® /XR (glipizide) Glynase® (glyburide micronized) Tolinase® (tolazamide) Micronase® (glyburide) Orinase® (tolbutamide) Prandin® (repaglinide) Starlix® (nateglinide)

Drug Class	Preferred Drugs	Non-preferred Drugs
Long-Acting Opioids (oral	Generic:	Generic:
tabs/caps/liquids) (*Not subject to	methadone	levorphanol
TIP. See pg. M.1.)	morphine sulfate SA/SR	oxycodone ER
	-	Oramorph SR
		fentanyl transdermal
		Brand:
		Avinza® (morphine sulfate
		ER)
		Duragesic® (fentanyl)
		transdermal
		Kadian <sup>®</sup> (morphine sulfate
		SR)
		Levo-Dromoran®
		(levorphanol)
		MS Contin <sup>®</sup> ( <i>morphine</i>
		sulfate SA)
		OxyContin <sup>®</sup> (oxycodone ER)
Non-Sedating Antihistamines	Generic:	Generic:
(*Not subject to TIP. See pg.	loratadine OTC	
M.1.)		Brand:
	Brand:	Allegra <sup>®</sup> (fexofenadine)
		Clarinex <sup>®</sup> (desloratadine)
		Claritin <sup>®</sup> (loratadine)
		Zyrtec <sup>®</sup> ( <i>cetirizine</i> )

Drug Class	Preferred Drugs	Non-preferred Drugs
Nonsteroidal anti-inflammatory	Generic:	Generic:
drugs (NSAID)	diclofenac potassium	Generic.
Cyclo-oxygenase - 2 (Cox-II)	diclofenac sodium	Brand:
Inhibitors	etodolac /XL	Anaprox <sup>®</sup> /DS (naproxen
Illilloltors		= =
	fenoprofen	sodium)
	flurbiprofen	Ansaid <sup>®</sup> (flurbiprofen)
	ibuprofen	Bextra® (valdecoxib)
	indomethacin	Cataflam <sup>®</sup> (diclofenac
	ketoprofen	potassium)
	nabumetone	Celebrex® (celecoxib)
	naproxen sodium	Clinoril® (sulindac)
	oxaprozin	Daypro <sup>®</sup> (oxaprozin)
	piroxicam	Feldene® (piroxicam)
	salsalate	Lodine® /XL (etodolac)
	sulindac	Mobic <sup>®</sup> (meloxicam)
	tolmetin	Motrin <sup>®</sup> ( <i>ibuprofen</i> )
		Naprelan <sup>®</sup> (naproxen) Naprosyn <sup>®</sup> /DS (naproxen) Orudis <sup>®</sup> (ketoprofen)
		Naprosyn <sup>®</sup> /DS (naproxen)
		Orudis® (ketoprofen)
		Oruvail® (ketoprofen)
		Relafen® (nabumetone)
		Salflex® (salsalate)
		Voltaren® /XL (diclofenac
O DI 11 /II.		sodium)
Overactive Bladder/Urinary	Generic short acting:	Generic short acting:
Incontinence	oxybutynin tablets/syrup	flavoxate
	<b>Brand long acting:</b>	Brand short acting:
	Vesicare® (solifenacin	Detrol <sup>®</sup> (tolterodine tartrate)
	succinate)	Ditropan <sup>®</sup> (oxybutynin
		chloride)
		Sanctura <sup>®</sup> (trospium
		chloride)
		Urispas <sup>®</sup> (flavoxate hcl)
		,
		Brand long acting:
		Detrol LA® (tolterodine
		tartrate)
		Ditropan XL® (oxybutynin
		chloride)
		Enablex <sup>®</sup> (darifenacin
		hydrobromide)
		Oxytrol® (oxybutynin
		chloride)

Drug Class	Preferred Drugs	Non-preferred Drugs
Proton Pump Inhibitors	Generic:	Generic:
	Prilosec OTC®	omeprazole Rx
	(omeprazole) tablets	
	Prevacid <sup>®</sup> (lansoprazole)	Brand:
	capsules	Aciphex <sup>®</sup> (rabeprazole)
	Prevacid <sup>®</sup> SoluTab	Nexium <sup>®</sup> (esomeprazole)
	(lansoprazole) *	Prilosec <sup>®</sup> Rx (omeprazole)
	Prevacid <sup>®</sup> Suspension	Protonix <sup>®</sup> (pantoprazole)
	(lansoprazole) *	Zegerid® (omeprazole)
	*EPA required	
Second Generation	Generic:	Generic:
Antidepressants	bupropion/SR**	fluvoxamine
*not subject to therapeutic	citalopram	nefazodone
interchange program (TIP).	fluoxetine HCl	
	mirtazapine/soltab	Brand:
	paroxetine HCl	Celexa® (citalopram)
		Cymbalta® (duloxetine HCl)
		Effexor /XR (venlafaxine)
		Lexapro® (escitalopram
		oxalate)
		Luvox® (fluvoxamine)
		Paxil® /CR (paroxetine HCl)
		Pexeva® (paroxetine
		mesylate)
		Prozac <sup>®</sup> /Prozac Weekly <sup>®</sup>
		(fluoxetine HCl)
		Remeron <sup>®</sup> /soltab
		(mirtazapine)
		Serzone <sup>®</sup> (nefazodone)
		Wellbutrin® /SR/XL
		(bupropion/SR) Zoloft <sup>®</sup> (sertraline)
		Zoloft <sup>®</sup> (sertraline)

Drug Class	Preferred Drugs	Non-preferred Drugs
Skeletal Muscle Relaxants	Generic:	Generic:
	baclofen	carisoprodol
	cyclobenzaprine	chlorzoxazone
	methocarbamol	orphenadrine
		tizanidine
		Brand:
		Dantrium® (dantrolene)
		Flexeril <sup>®</sup> (cyclobenzaprine)
		Lioresal <sup>®</sup> (baclofen)
		Norflex <sup>®</sup> (orphenadrine)
		Parafon Forte®
		(chlorzoxazone)
		Robaxin <sup>®</sup> ( <i>methocarbamol</i> )
		Skelaxin <sup>®</sup> (metaxalone)
		Soma® (carisoprodol)
		Zanaflex® (tizanidine)
Statin-type cholesterol-lowering	Generic:	Generic:
agents	lovastatin	
		Brand:
	Brand:	Lescol® /XL (fluvastatin)
	Lipitor® (atorvastatin)	Mevacor <sup>®</sup> ( <i>lovastatin</i> )
	Pravachol® (pravastatin)	Zocor <sup>®</sup> (simvastatin)
Targeted Immune Modulators	Generic:	Generic:
	Brand:	Brand:
	Enbrel® (etanercept)*	Humira <sup>®</sup> (adalimumab)*
	Remicade® (infliximab)*	Kineret <sup>®</sup> (anakinra)*
		Raptiva® (efalizumab)*
	*EPA required	*EPA required

#### **Prescription Drug Program**

Drug Class	Preferred Drugs	Non-preferred Drugs
Triptans	Generic:	Generic:
	Brand:	Brand:
	Amerge <sup>®</sup> (naratriptan)	Maxalt <sup>®</sup> (rizatriptan)
	Axert <sup>®</sup> (almotriptan)	Zomig <sup>®</sup> nasal spray
	Frova <sup>®</sup> ( <i>frovatriptan</i> )	(zolmitriptan)
	Imitrex <sup>®</sup> injection	
	(sumatriptan)	
	Imitrex <sup>®</sup> nasal spray	
	(sumatriptan)	
	Imitrex <sup>®</sup> tablets	
	(sumatriptan)	
	Maxalt MLT® (rizatriptan)	
	Relpax <sup>®</sup> ( <i>eletriptan</i> )	
	Zomig <sup>®</sup> /ZMT	
	(zolmitriptan)	

	Prescription Drug Program
This pa	age intentionally left blank.
Rev. 05/31/2006 Eff. 07/01/2006)  4 Memo 06-32	- N.12 - Washington PDL Included due to page numbering changes.